Arbutus Biopharma Investor Relations Material
Latest events
Status Update
Arbutus Biopharma
Q1 2025
14 May, 2025
Q4 2024
27 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Arbutus Biopharma Corporation
Access all reports
Arbutus Biopharma Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for viral diseases. The company utilizes its expertise in RNA interference (RNAi) technology and small molecule development to address diseases such as chronic hepatitis B. Arbutus conducts research and development to advance its proprietary drug candidates and explore combination treatment approaches. The company is headquartered in Warminster, Pennsylvania, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ABUS
Country
🇺🇸 United States